224 results about "Metabolic function" patented technology

The present invention relates to methods of treating metabolic dysfunction-associated steatohepatitis (MASH) in a human subject, comprising administering to the subject a therapeutically effective amount of indeglitazar or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to application of beta-hydroxybutyrate in preparation of a medicine for preventing or treating hepatocellular carcinoma. The invention provides an application of beta-hydroxybutyrate in preparation of a medicine for preventing and / or treating hepatocellular carcinoma. The beta-hydroxybutyrate comprises a beta-hydroxybutyrate or a combination of a plurality of beta-hydroxybutyrates. A series of experimental data show that beta-hydroxybutyrate not only can effectively improve fatty degeneration and inflammatory response of hepatocytes, but also can remarkably reduce the risk of occurrence of metabolic dysfunction related hepatocellular carcinoma (HCC), and can inhibit malignant biological characteristics of HCC. The invention provides a powerful scientific basis for the development of novel HCC prevention and treatment medicines, and has a wide clinical application prospect.

The invention relates to the technical field of hyperbaric oxygen physiotherapy cabins, in particular to a terahertz wave micro hyperbaric oxygen physiotherapy cabin which comprises a cabin body, a door opening is formed in one face of the cabin body, a cabin top is installed at the top of the cabin body, and a door plate is hinged to the interior of the door opening through a hinge; the deep sea volcanic energy stone treatment device comprises a cabin, two groups of bed bodies are arranged in the cabin, the two groups of bed bodies are symmetrically mounted in the cabin, each bed body is of a hollow structure, and a plurality of terahertz wave generation modules are uniformly laid on the upper surface of each bed body through a support. The pelelith-based passive terahertz releaser formed after the pelelith-based passive terahertz releaser is combined with the ceramic matrix can continuously release terahertz waves with the frequency band of 0.1-12 THz, the vibration frequency is consistent with that of human cells, and the terahertz waves with the frequency band can repair biological enzyme and nucleic acid structure deformation caused by free radical attack and age increase through the biological resonance effect, so that the pelelith-based passive terahertz releaser can be used for repairing biological enzyme and nucleic acid structure deformation caused by free radical attack and age increase. The metabolic function is recovered from the cell molecule level, and the defect that a traditional oxygen cabin can only supply oxygen on the surface layer and cannot be deeply repaired is overcome.

The invention provides a microbial ecological interaction mechanism determination method and device, and relates to the technical field of species correlation research. The method comprises the following steps: determining N microorganisms and abundance thereof based on metagenome data of a target environment sample; determining the abundance grade and correlation based on the abundance of the ith microorganism and the jth microorganism; carrying out metabolic function annotation on the i microorganism and the j microorganism based on a reference genome, and calculating a function overlapping ratio; determining a community construction mechanism based on the abundance correlation and the function overlapping ratio; based on the function overlapping difference, determining a function overlapping grade change; and determining the ecological interaction mechanism of the i and j microorganisms according to the information. The method can be used for systematically revealing a species coexistence mechanism and a metabolic interaction relationship thereof in the microbial community.

The invention discloses a synthetic microbial agent for treating uranium-contaminated soil and a preparation method of the synthetic microbial agent. The synthetic microbial agent is prepared from the following bacteria: P.adami, P.megatherium, bacillus subtilis, Artobacter volluticus, symbiotic fungi, Aspergillus niger, sulfate reducing bacteria and Shewanella. The symbiotic fungi are mucor lastein, mucor unimingguminum, mucor circinelloides, mucor dense, rhizopus arrhizus and phylum phthochytrium parasitic fungi. The prepared synthetic microbial agent and synthetic microbial embedded balls are applied to uranium-contaminated soil remediation, the key enzyme activity can be effectively improved, the soil metabolism function is enhanced, meanwhile, exchangeable uranium with high ecological risk is converted into stable and low-harm residual uranium, the mobility and bioavailability of uranium in soil are effectively weakened, and the uranium-contaminated soil remediation effect is improved. Therefore, immobilized remediation of uranium is realized, and a good soil uranium fixing effect is achieved.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention provides a composition for reducing uric acid and relieving gout and a preparation method thereof, and relates to the technical field of products for reducing uric acid and relieving gout. The composition comprises the following raw materials: 18-24 parts of phellinus igniarius, 9-13 parts of sunflower disc small molecule peptide extract, 3-7 parts of corn stigma, 4-6 parts of poria cocos, 2-5 parts of pawpaw, 3-6 parts of liquorice, 2-5 parts of astragalus extract and 3-6 parts of lettuce extract. The preparation method of the sunflower disc small-molecule peptide extract comprises the following steps: carrying out enzymolysis on sunflower disc powder twice, carrying out membrane filtration to obtain a sunflower disc small-molecule peptide solution, reacting the sunflower disc small-molecule peptide solution with chitosan oligosaccharide and transglutaminase, and carrying out freeze drying to obtain the sunflower disc small-molecule peptide extract. Through the proper raw material composition and proportion, the metabolic function can be effectively regulated to promote excretion of uric acid, so that the content of xanthine oxidase and adenosine deaminase in the liver is obviously reduced, the uric acid level is effectively reduced, the intestinal probiotic structure can be stabilized, the immunity is enhanced, the kidney is protected, and the good effects of reducing uric acid and relieving gout are achieved.

The invention relates to the technical field of medical assistance, in particular to a depression risk assessment method and system based on intestinal flora characteristics. The method comprises the following steps: acquiring an individual enteric microorganism sample, performing nucleic acid sequencing on the enteric microorganism sample, and determining abundance data of functional genes related to a neural activity metabolic pathway in enteric microorganisms; carrying out metabolite detection on the intestinal microorganism sample, and determining concentration data of metabolites related to the neural activity metabolic pathway in the intestinal microorganisms; based on the abundance data of the functional genes and the concentration data of the metabolites, data fusion processing is carried out, a neural activity metabolism function spectrum is constructed, and the neural activity metabolism function spectrum is a multi-dimensional feature vector; and inputting the neural activity metabolic function spectrum into a pre-trained risk assessment model, and outputting a depression risk score of the individual. The accuracy and repeatability of evaluation are remarkably improved, and the method has great potential for early screening, dynamic monitoring and personalized health management.

The invention provides a single strain metabolism characteristic chromatogram database of oral key microorganisms in a high-glucose microenvironment and a construction method and application thereof, and belongs to the technical field of oral microbiology. The method comprises the following steps: simulating an intraoral high-glucose microenvironment in vitro; the method comprises the following steps: carrying out standardized single-strain culture on oral key microorganisms, carrying out whole-spectrum metabolism detection (non-targeted liquid chromatography-mass spectrometry (LC-MS) and non-targeted gas chromatography-mass spectrometry (GC-MS) on culture supernatant, and identifying and analyzing metabolism to construct a single-strain metabolism characteristic spectrum database of the oral key microorganisms in a high-glucose microenvironment. The database can be used for source attribution and cross validation of in-vivo metabolome results, and assists in screening key metabolites and key pathways related to high glucose. According to the method, the reliability of metabolite source judgment is improved, the directional influence of high glucose on the flora metabolism function is revealed, the method is standardized, and resources are platformized.

The invention belongs to the technical field of bioengineering and microbiomics, and particularly relates to an acquisition method and application of a specific metabolic substrate of lactobacillus crispatus and application of a specific carbohydrate active enzyme CAZzyme gene and a polysaccharide utilization site (PUL). Genomes of lactobacillus crispatus and lactobacillus inertus are obtained from a public database, gene annotation is carried out on the genomes of the lactobacillus crispatus and the lactobacillus inertus, and a random forest model and a KEGG metabolic pathway diagram are combined to find specific CAZzyme genes, PUL and other genes with metabolic functions of the lactobacillus crispatus; a substrate which only lactobacillus crispatus can metabolize is searched based on the genome difference of the two bacteria, and the ability of the obtained substrate for promoting the growth of lactobacillus crispatus and inhibiting the growth of inert lactobacillus is evaluated through experiments. Growth and reproduction of the lactobacillus crispatus are promoted through the substrates, so that the lactobacillus crispatus accounts for a higher proportion in vagina microecology, the vagina is protected, and reproduction of other unfavorable bacteria is reduced. The assisted reproduction success rate is improved.

This invention provides a method for monitoring and evaluating the risk of pathogenic bacteria transmission in poultry farm feces, belonging to the field of livestock and poultry biosecurity control technology. The method includes evaluating the risk of Salmonella transmission during the poultry physiological cycle, assessing the risk of antibiotic resistance associated with drug administration behavior, and monitoring the function during composting based on microbial community structure and metabolic function. This invention can accurately locate the highest-risk nodes of pathogen contamination and antibiotic resistance evolution during the breeding cycle, solving the problem of inaccurate identification of risk sources in existing technologies and avoiding poultry product contamination due to missed risk assessments. It overcomes the single-dimensional limitation of existing technologies that only detect the quantity of pathogens, comprehensively evaluating pathogen risk from phenotypic, molecular, and functional levels. The assessment results are more in line with the actual biosecurity needs of poultry farming, ultimately reducing the safety risks of poultry product contamination and the spread of antibiotic resistance.

Provided are novel compounds for GIPR, GLP-1R and GCGR. Specifically, provided are GLP-1R / GIPR / GCGR triagonists peptides, and conjugates comprising an Fc fragment and GLP-1R / GIPR / GCGR triagonists peptides. Pharmaceutical compositions comprising these compounds,as well as uses thereof in treating metabolic conditions and disorders, such as diabetes mellitus, type 2 diabetes, obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatohepatitis (MASH), and non-alcoholic steatohepatitis (NASH) are also provided.

The application discloses an Akkermansia muciniphila branched-chain amino acid metabolism gene nifJ and application thereof in colostrum IgA synthesis, and belongs to the technical field of genetic engineering. The application finds through in-vivo and in-vitro tests that the nifJ is a branched-chain amino acid metabolism gene of the Akkermansia muciniphila, regulates the metabolism process from branched-chain amino acids to branched-chain short-chain fatty acids, and plays a key role in the synthesis of maternal colostrum IgA. The research result of the application is expected to clarify the interaction relationship between the metabolic function of the Akkermansia muciniphila and a host, and reveal the action mechanism of the Akkermansia muciniphila in regulating the synthesis of maternal colostrum IgA, thereby providing a theoretical basis for improving the maternal colostrum IgA and further improving the maternal reproductive performance.

The invention relates to the technical field of biological medicines, and particularly discloses application of ebbeselenium in preparation of a medicine for treating male delayed gonadal hypofunction. After the ebbeselenium is adopted for intervention, the autophagy activity of testicular interstitial cells of old mice is increased, lipid autophagy is enhanced, testosterone synthesis is promoted, the serum testosterone level is remarkably improved, and the symptoms of male delayed hypogonadism (LOH) are effectively relieved; ebbeselenium simultaneously shows a relatively good delaying effect on senescence of a plurality of organs. The ebbeselenium can improve the reproductive capacity, the behavior memory capacity, the athletic capacity and the metabolic function of old mice at the same time, and synergistic and effective treatment of low serum testosterone and LOH complications is achieved. Besides, by enhancing the molecular reduction effect of PRDX1 targeting ATG4B, the ebbeselenium regulates and controls the autophagy pathway of testicular interstitial cells and enhances the functions of the testicular interstitial cells so as to promote synthesis of testosterone, and a new treatment strategy is provided for treatment of LOH.

The invention provides a nano-phase penthorum chinense pursh extract, which is prepared by the following steps: soaking a penthorum chinense pursh medicinal material, decocting, filtering, collecting filtrate, carrying out layering centrifugation to remove precipitate, dialyzing supernate by adopting a dialysis bag with the molecular weight cutoff of 3.5 kDa, and freeze-drying dialysate to obtain the nano-phase penthorum chinense pursh extract. The invention further provides a preparation method and application of the nanometer phase-state penthorum chinense pursh extract. The invention provides an extraction method capable of accurately separating 50-200nm phase-state active components in a nanometer phase-state penthorum chinense pursh extract traditional Chinese medicine. Organic solvents are prevented from being used, and the safety of extracted products is improved; the purity of the target component is improved; the structural integrity of a natural nanometer phase state is kept; the obtained nanometer phase-state extract has the effects of remarkably improving metabolic dysfunction related steatohepatitis and resisting coagulation, is high in separation efficiency, can be completed in 2-3 days, and can be applied on a large scale; the equipment is simple and low in cost.

Despite the high prevalence and serious clinical implications of metabolic associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), MASH is usually overlooked in clinical practice, due to the lack of accurate biomarkers. The inventors evaluated the ability of plasma large extracellular vesicles (lEVs) to serve as noninvasive biomarkers for the diagnosis of MASH, in particular in T2D patients. Proteomic analysis identified Transferrinreceptor on lEVs (TFRC-lEVs) as associated with MASH. The inventors thus measured TFRC- lEVs on plasma samples from patients included in the derivation cohort. The proportion of patients with TFRC-lEVs concentration > 61 ng / mL was significantly higher in patients with MASH than in those with steatosis. TFRC-lEVs > 61 ng / mL remained associated with MASH after adjustment on either usual laboratory variables, or on the NASH-Test or on the Fibroscan FAST-score. When combining TFRC-lEVs with available methods the population suspected of having MASH was 32% and 29%, versus 22% and 16% for NASH-test or FAST score alone, without decreasing specificity. In conclusion, TFRC-lEVs, a marker of hepatocyte ballooning, is a promising biomarker for MASH. It could be used for patients' screening to enlarge recruitment of patients with MASH in clinical trials.

The invention discloses China-hemp peptide multi-nutrient protein powder with a metabolism improving function, which comprises China-hemp seeds, soybean protein isolate, China-hemp seed protein, chickpea protein, pea protein, China-hemp peptide, rice protein, broad bean protein, mung bean protein and wheat hydrolyzed protein. Wherein the Chinese hemp seeds are 15-25 parts, the soybean protein isolate is 10-20 parts, the Chinese hemp seed protein is 5-15 parts, the chickpea protein is 8-12 parts, the pea protein is 8-12 parts, the Chinese hemp peptide is 8-15 parts, the rice protein is 5-10 parts, the broad bean protein is 5-10 parts, the mung bean protein is 5-10 parts, and the like. According to the present invention, besides the protein nutrition, the small molecule peptide and 10 other nutrients such as Omega3, gamma-linolenic acid, vitamin E and a variety of minerals are contained, such that the complete protein nutrition is provided, and the health-care food is rich in Omega-3 fatty acid, gamma-linolenic acid, vitamin E, potassium, magnesium, zinc and other minerals with different molecular magnitudes extracted from China-hemp seeds, the ten nutrients, a plurality of plant proteins and small molecule peptides have a synergistic effect to jointly form a basis for improving the metabolic function.

The present application relates to a kind of preparation method of Fugunkang composition and its detection method, the preparation method is cut into section, first using red koji and saccharomyces cerevisiae combined fermentation extraction, dregs is extracted with water before boiling, concentrate and extract the fermentation liquor and water, it is obtained.The metabolic function of microorganism is fully utilized, promote the release and absorption of effective components of traditional Chinese medicine in vivo, so as to improve the curative effect of traditional Chinese medicine, reduce the side effect of traditional Chinese medicine.The detection method includes spray agent in just bed, parsnip medicine thin layer identification and the content detection of rutin, hypericin;The thin layer identification can identify just bed and parsnip medicine under the same chromatographic condition, the content detection increases the content detection of hypericin on the basis of original, and the content of rutin and hypericin can be determined simultaneously, save the detection cost, ensure the quality of raw material and finished product.

This disclosure presents systems and methods for baroreflex activation therapy (BAT) to regulate inflammation by modulating autonomic nervous system activity. Electrical stimulation is delivered to one or more baroreceptors, and real-time physiological signals are monitored, including inflammatory biomarkers (e.g., TNF-α, IFN-γ, IL-1, IL-6, IL-12, CRP) and autonomic parameters such as heart rate variability (HRV). A closed-loop feedback module analyzes biomarker fluctuations and autonomic balance changes and dynamically modifies stimulation parameters, including amplitude, pulse width, frequency, and duty cycle, to suppress systemic inflammation and restore autonomic balance. In certain embodiments, multi-channel stimulation architectures and AI-driven algorithms or machine learning models analyze biomarker trends and historical patient response patterns to optimize therapy. The disclosed BAT systems and methods may be used to treat inflammatory diseases, autoimmune disorders, cancer progression, chronic inflammatory pain conditions, arrhythmias associated with inflammation, and metabolic dysfunction.

The research finds that the SUMOylation level of the liver in a clinical specimen and an animal model of the metabolic dysfunction fatty liver disease is obviously reduced. UBC9 is used as the only key E2 ligase for SUMOylation to regulate and control the SUMOylation level. The invention discloses application of a UBC9 gene overexpression preparation in drugs for treating or preventing metabolic dysfunction fatty liver diseases. Through overexpression of liver specificity UBC9 mediated by an AAV adeno-associated virus vector or overexpression of UBC9 in HepG2 cells by a lentiviral vector, lipid deposition of a C57 mouse liver induced by high fat diet and a cell model treated by palmitate can be remarkably improved, and reduction of the SUMOylation level of the mouse liver and the human HepG2 cells under the high fat background can be reversed. Therefore, the UBC9 gene overexpression preparation can be used for developing drugs for treating metabolic dysfunction fatty liver diseases.

The present disclosure is directed to a method of monitoring treatment of metabolic dysfunction-associated steatohepatitis (MASH) in a patient by initiating a treatment by administering Compound 1: (Compound 1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient, determining percentage increase in the level of SHBG from baseline, and continuing administration of Compound 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient if the percentage increase in the level of SHBG is at least 50% from baseline.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

The invention discloses a black pepper extract-containing composition capable of promoting intestinal digestion and absorption and a cat food, and relates to the technical field of animal foods.The composition is prepared by compounding fish oil, krill oil, sunflower seed oil and linseed oil according to a specific proportion based on compound functional grease and natural plant extracts in a scientific proportion; according to the invention, the ratio of omega6 fatty acid to omega3 fatty acid is optimized to an ideal range of (2.5-3.2): 1, black pepper extract with functions of promoting digestion and regulating flora is synergistically added, and through combination of scientifically proportioned functional components and an advanced process, an'intestinal tract-microorganism-metabolism 'experiment verifies that digestion and absorption of cat nutrition are realized, and the effect of promoting digestion and regulating flora is achieved. Meanwhile, the multi-dimensional and systematic improvement of oxidation resistance, inflammation resistance, immunity improvement and metabolism functions is achieved.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

The invention belongs to the technical field of medical evaluation, and relates to a method for evaluating damage of air pollution to human skin health based on a PPO-LSTM fusion algorithm. The method comprises the following steps: acquiring multi-source data; preprocessing data, and constructing a multi-dimensional time sequence feature data set; establishing a PPO-LSTM fusion model, performing feature extraction and reinforcement learning optimization on the multi-dimensional time sequence features, and outputting skin health core indexes; performing prediction and quantitative evaluation on the functional states of the cuticle, the epidermal layer and the corium layer; generating a personalized nursing decision scheme for skin health maintenance; outputting corresponding early warning information and coping suggestions by judging the risk levels of the skin barrier function and the dermal metabolism function; and updating parameters of the skin health injury evaluation model. According to the method, multi-dimensional data are integrated in the same model at the same time, the evaluation dimension is more comprehensive, the accuracy of skin health injury evaluation is improved, and a complete closed loop from detection evaluation to nursing scheme generation and risk prompt is realized through decision making and early warning.

The invention belongs to the field of medicine, and particularly relates to application of apium graveolens extract to preparation of medicine for treating fatty liver diseases related to metabolic dysfunction. The celery and sophora flower extract is an alcohol extract of celery seeds and sophora flower buds in a weight ratio of (1: 1)-(4: 1), preferably (3: 1)-(4: 1), and further preferably (3: 1). The invention provides a new choice for clinical medication for treating fatty liver diseases related to metabolic dysfunction, and has great clinical value and social significance.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD), is a condition characterized by the accumulation of fat in the liver of individuals with no alcohol consumption, and at least one cardiometabolic risk factor (overweight / obesity, high blood pressure, high blood sugar, high triglycerides levels, low HDL-C levels). The inventors demonstrated that Rab30 silencing improve metabolic dysfunction–associated steatotic liver disease (MASLD). The present invention relates to a method for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) in a subject in need thereof comprising the administration of a therapeutically effective amount of an inhibitor of Rab30.

The invention provides a traditional Chinese medicine composition which comprises the following components in parts by weight: 32-34 parts of rumex hanus, 20-31 parts of dandelion, 20-32 parts of uncaria rhynchophylla and 15-35 parts of gastrodia elata. And at least one of the following six traditional Chinese medicines in parts by weight: 17-37 parts of radix paeoniae alba, 15-20 parts of lumbricus, 10-45 parts of eucommia ulmoides, 22-34 parts of longan seeds, 20-37 parts of tribulus terrestris and 10-30 parts of herba siegesbeckiae. The traditional Chinese medicine composition is taken by adopting deuterium-depleted water. The combination of the traditional Chinese medicinal materials has a synergistic effect in the aspects of treating hypertension, hyperlipidemia and metabolic syndrome, the traditional Chinese medicinal materials respectively contain different active ingredients, the overall curative effect is enhanced by regulating blood pressure, blood fat and metabolic functions through multiple targets, and in order to enable the traditional Chinese medicinal composition to better exert the drug effect, the traditional Chinese medicinal composition has a remarkable curative effect. Preferably, the deuterium-depleted water is matched with the traditional Chinese medicine composition to be taken, and the effect of the deuterium-depleted water is developed by 1-2 times.

The invention relates to the technical field of neonatal inherited metabolic disease screening, and discloses a neonatal inherited metabolic disease screening auxiliary system. The system comprises a multi-source information acquisition module, an information standardization module, a dynamic metabolism image construction module, an anomaly detection and analysis module and a screening management optimization module. The system integrates blood metabolites, gene variation, clinical signs and other multi-source information of newborns, constructs a metabolic function image showing dynamic changes and interaction relations of the metabolites, recognizes metabolic abnormality areas and development situations according to the metabolic function image, and generates a personalized screening management plan. Metabolic network visualization analysis is realized through a dynamic image, and an anomaly detection algorithm is continuously optimized by utilizing planned execution feedback data. According to the system, the trend evaluation of the metabolic state and the self-adaptive iteration of the screening strategy are realized, and the screening accuracy and the management individualization level are improved.

Provided herein is a noninvasive method for measuring pH, glucose and glycogen levels using a single acquisition method, as well as systems for performing the method. This method for glycogen / glucose (and pH) detection has high specificity enabled by superior chemical shift separation in high-strength magnetic fields. The methods have applications in detecting changing tumor microenvironments in cancerous cells for measuring important metrics for noninvasive and quantitative metabolic profiling.